Animal Antibacterial Peptide 2024 Market Research Report
Download The Full Brouchre of Report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18662
The use of low levels of antibiotics in animal feed as growth promoters and rise in use of antibiotics in animal and human infections are causes of antibiotics resistance among gram negative, gram positive, and bacterial pathogens. The natural and synthetics antibacterial peptides are good candidates for antibiotics alternatives. The natural antibiotics are rich source of proteins as well as amino acids and have less side effects as compared to synthetic antibiotics. They possess synergistic activity with conventional antibiotics and promote wound healing. Domestic animals are good source of antibacterial peptides. The antibacterial peptides are expressed in many polymorphonuclear leukocytes, tissues, macrophages, and mucosal epithelial cells. Antibacterial peptides are preserved in their function, structure, and mechanisms of action. Thus, it is attractive to speculate that synthetic antibacterial peptides or their congeners might be used to prevent or treat infections. Antimicrobial peptides are good applicants for the design of new antimicrobial agents for specific application because of their low propensity for the development of bacterial resistance and natural antimicrobial properties. The major driving factor of antibacterial peptides is their ability to kill multi drug resistance bacteria.
The market of animal antibacterial peptide is segmented on the basis of peptide type, product origin, and geography. On the basis of peptide type, the animal antibacterial peptide market is segmented as linear cationic α-helical peptides, anionic peptides, cationic peptide containing specific amino acid, and anionic & cationic peptides that possess cysteine and form disulfide bonds. Anionic peptides are rich in glutamic and aspartic acids whereas cationic peptides are rich in arginine, phenylalanine, glycine, tryptophan, and proline. These peptides are good candidates for supplements to conventional antibiotic therapy and for development as novel therapeutic agents. These are broad spectrum in nature and possess bactericidal activity. Insect’s peptides are one of the largest groups of antimicrobial peptides. Cecropins constitute the most important host defense system against bacterial infection. By product origin, the animal antibacterial peptide market is segmented into cattle origin, sheep origin, goat origin, pig origin, horse origin, and poultry. The animal antibacterial peptides are derived from above sources.
Browse Global Strategic Business Report: http://www.transparencymarketresearch.com/animal-antibacterial-peptide-market.html
By geography, the market for animal antibacterial peptide is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to dominate the market. The rise in research is the key driving factor of the animal antibacterial peptide market in North America. Asia pacific is the most progressive region for the animal antibacterial peptide market. The rise in expenditure on animal health care is a key factor responsible for growth of the market. The increasing resistance to conventional antibiotics is likely to be the key driver of the animal antibacterial peptide market during the forecast period. Furthermore, the rise in use of antibiotics to treat various infections and disease in animal feed is projected to fuel the growth of the animal antibacterial peptide market during the forecast period.
Major players operating in the animal antibacterial peptide market include Zoetis, Merck Animal Health, Merial, Elanco (Eli Lilly and Company), Bayer HealthCare, Animal Medics, Biogenesis Bago, and Boehringer Ingelheim Vetmedica. The rising demand for alternatives for conventional antibiotics is estimated to increase the competition between market players of animal antibacterial peptide.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Animal Antibacterial Peptide 2024 Market Research Report here
News-ID: 500700 • Views: 490
More Releases from Transparency Market Research – Pharmaceutical
Plasma Protease C1-inhibitor Treatment Market Estimated to Flourish by 2025
A fresh market intelligence study by Transparency Market Research (TMR) states that the business landscape of the global plasma protease c1-inhibitor treatment market is consolidated with intense competitive rivalry among leading players. TMR detects Shire plc led the global plasma protease C1-inhibitor treatment market in 2016. Key factors that account for its dominance are expanded product portfolio, acquisitions, and widespread market presence. Pharming Group N.V., CSL Limited, and Sanquin are
Narcolepsy Market - Global Industry Trends and Forecast - 2019
Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors. Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is
Diabetic Macular Edema Market - Key Growth Factors and Forecast 2019
Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling. Due to such swelling, a person’s central eye vision gets distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). Obtain Report Details @ http://www.transparencymarketresearch.com/diabetic-macular-edema-market.html Diabetic macular edema is the major reason for loss of vision in patients
Primary Systemic Amyloidosis Market- Get Facts About Business Strategies and Fin …
Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. There are various types of amyloidosis out of which primary systemic amyloidosis are most common, these are associated with plasma cell dyscrasia and has no historical evidence of disease. Kidney, intestines, liver, heart and nerves are the common organs
More Releases for Antibacterial
Global Antibacterial Drugs Market Research Report
This report studies the global Antibacterial Drugs market status and forecast, categorizes the global Antibacterial Drugs market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer AG Pfizer Inc. Sanofi GlaxoSmithKline Plc. (GSK) Merck & Co., Inc. AstraZeneca Johnson and Johnson Bristol
Global Antibacterial Drugs Market: Regional Overview
The global antibacterial drugs market features a fairly competitive landscape and leading players include Allergan, Plc., Novartis AG, Bristol Myers Squibb Company, Johnson and Johnson, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi, Pfizer Inc., Bayer AG, notes Transparency Market Research (TMR). Over the years, the competition in the market is expected to intensify. A number of prominent players are focusing on entering into strategic collaborations and mulling
Antibacterial Drugs Market: Regional & Competitive Analysis
The global antibacterial drugs market, according to TMR, could expand at a CAGR of 1.30% between 2015 and 2023 to achieve a revenue valuation of nearly US$38.9 bn by the final forecast year. Although β-lactams had dominated the market in the past with a larger share, the drug class could lose its share to miscellaneous antibacterials, which are projected to rise at a higher growth rate during the forecast period.
Antibacterial Drug Development Market Pipeline Review 2017
Antibacterial Therapies Drug Development Pipeline Review 2017 report covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the
Antibacterial Drugs Market - Global Industry Insights 2024
Prevalence of bacterial infections and diseases is especially high in third world countries and significantly hampers quality of life across the globe. Further adding to the woes of the affected population is the increasing strains of bacteria that are resistant to conventional antibacterial drugs. The epidemic of antibacterial resistance has spurred interest among the global healthcare organizations and a few pharmaceutical companies and research institutes to develop next-generation antibacterial
US FDA Prohibits 19 Antibacterial Soap Ingredients
The US Food and Drug Administration (FDA) has issued a final rule regarding 19 ingredients in over-the-counter (OTC) consumer antiseptic products intended for use with water. The FDA has now determined that these 19 ingredients are not generally recognized as safe and effective (GRAS/GRAE) and so, without an approved new drug application, products containing these ingredients are now considered misbranded – effective September 6, 2017. The US FDA issued its final